478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

Antonella Palazzo, Angela Toss, Rossella Graffeo, Andrea Fontana, Matteo Lambertini, F. Pantaleo, Marta Perachino, Marta Nerone, Nadia Bianco, Patrizia Vici, Laura De Marchis, Nicoletta Staropoli, L. Rinaldi, Antonella Lai, Gian Paolo Spinelli, E. Di Monte, Francesco Giotta, Alessandra Gennari, Laura Cortesi, Emilio Bria